| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 6,322,000 | 5,662,000 | 5,909,000 | 5,482,000 | 6,329,000 |
| Sales Growth | +11.66% | -4.18% | +7.79% | -13.38% | +16.71% |
| Net Income | 588,000 | 552,000 | 530,000 | 474,000 | 616,000 |
| Net Income Growth | +6.52% | +4.15% | +11.81% | -23.05% | +31.34% |
Siemens Healthineers Ag (SHL.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2024) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (17% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (20%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. Americas represents 42% of total sales, Europe, Middle East, and Africa 33%, and Asia-Pacific including China the remainder.
Fiscal Year End Date: 09/30